# China Drug Repurposing Market

> China Drug Repurposing Market Research Report: Size, Share, Trend Analysis By Typess (Disease-centric, Target-centric, Drug-centric), By Therapeutic Area (Same Therapeutic Area, Different Therapeutic Area) and By Drug Molecules (Biologics, Small Molecule) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 15.0%
- **2024:** $ 30 Million
- **2025:** $ 34.5 Million
- **2035:** $ 139.6 Million
- **Key Players:** Pfizer Inc (US), Novartis AG (CH), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), AstraZeneca PLC (GB), Eli Lilly and Company (US), Gilead Sciences Inc (US), Amgen Inc (US)

**Report ID:** MRFR/Pharma/50637-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/china-drug-repurposing-market-52395

---

## Market Summary

## **China Drug Repurposing Market Overview**

As per MRFR analysis, the China Drug Repurposing Market Size was estimated at 18 (USD Million) in 2023. The China Drug Repurposing Market Industry is expected to grow from 20.28(USD Million) in 2024 to 93.65 (USD Million) by 2035. The China Drug Repurposing Market CAGR (growth rate) is expected to be around 14.922% during the forecast period (2025 - 2035)

**Key China Drug Repurposing Market Trends Highlighted**

The China Drug Repurposing Market is seeing significant growth fueled by various key market drivers. Increased government support and funding for innovative healthcare solutions have been pivotal. The Chinese government has actively encouraged research in drug repurposing as part of its broader healthcare reform initiatives. This focus is highlighted by policies that aim to enhance patient outcomes and enable faster access to essential medicines. Furthermore, the growing prevalence of chronic diseases in China is steering attention towards repurposed drugs that can provide new treatments for these conditions. 

Opportunities to be explored include partnerships between pharmaceutical companies and academic institutions.Such collaborations can accelerate research and development processes, especially in regions with a high concentration of medical research facilities. Additionally, there is immense potential in leveraging advanced technologies like artificial intelligence and big data analytics to identify existing drugs that may be effective for treating other diseases. These technologies can significantly enhance the efficiency and success rate in drug repurposing initiatives. 

Recent trends in China are marked by an increasing number of clinical trials regarding drug repurposing, indicating a shift toward a more proactive approach in tackling healthcare challenges.The COVID-19 pandemic has also sparked a surge in interest in repurposed drugs, underscoring their importance in addressing immediate health crises. 

Moreover, as Chinese patients become more informed and engaged in their healthcare decisions, the demand for innovative treatments, including repurposed drugs, is likely to rise. Overall, the landscape for drug repurposing in China is evolving to meet both patient needs and healthcare goals.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**China Drug Repurposing Market Drivers**

**Increasing Healthcare Expenditure in China**

The China Drug Repurposing Market Industry is being greatly fueled by the country's rising healthcare costs. Healthcare spending in China reached over 6.1 trillion Yuan in 2021, up about 9.8% from the year before, according to the National Health Commission of China. The drug repurposing strategy is becoming more popular because of its efficiency and cost-effectiveness as the government works to improve healthcare services and access to reasonably priced pharmaceuticals. 

Prominent groups such as the China Pharmaceutical Association are advocating for the advantages of repurposing current medications, which can speed up the course of therapy for a number of illnesses. It is anticipated that this rise in healthcare spending would spur research and innovation in the drug repurposing industry, improving the chances for overall market expansion.

**Rising Prevalence of Chronic Diseases**

The China Drug Repurposing Market Industry is witnessing robust growth due to the escalating prevalence of chronic diseases such as diabetes and cardiovascular diseases. Recent statistics from the Chinese Center for Disease Control and Prevention indicate that the number of people living with diabetes is projected to reach 140 million by 2030, illustrating a rise in healthcare challenges. 

Organizations like the Chinese Diabetes Society are, together with healthcare stakeholders, advocating for the repurposing of existing medications to treat chronic conditions more effectively.By redirecting current treatments for new uses, the China Drug Repurposing Market can cater to the urgent needs presented by this growing patient demographic.

**Supportive Government Policies and Initiatives**

Chinese government policies are fostering a conducive environment for the growth of the China Drug Repurposing Market Industry. With the '14th Five-Year Plan' prioritizing improving healthcare innovation and drug accessibility, the state is enhancing regulatory frameworks to encourage drug repurposing. Major initiatives include streamlined approval processes for repurposed drugs to reduce the time and costs associated with bringing these products to market.

The National Medical Products Administration of China is pioneering efforts in these areas, which are likely to stimulate greater research and development activities, thereby propelling market growth significantly. This government support not only enhances the feasibility of drug repurposing but also encourages collaboration among pharmaceutical companies.

**China Drug Repurposing Market Segment Insights**

**Drug Repurposing Market Types Insights**

The China Drug Repurposing Market has been demonstrating significant growth, with a strong focus on its Types segmentation, which includes Disease-centric, Target-centric, and Drug-centric approaches. The Disease-centric approach is particularly important, as it focuses primarily on the various diseases that can be treated with existing drugs, providing a quicker and often more cost-effective way to address healthcare needs. This is especially relevant in China due to the rising burden of chronic diseases, where innovative therapies can lead to improved patient outcomes with reduced development times.

The Target-centric approach provides another layer of specificity, emphasizing the biological mechanisms and targets within the human body to identify existing drugs that may be effective against different conditions. This method is gaining traction, as it allows for the identification of new uses for established drugs, thereby increasing therapeutic options available for patients and maximizing existing resources. The Drug-centric approach is also noteworthy, concentrating on the existing pharmaceuticals themselves and exploring alternate utilizations beyond the original indications.

This segment holds a strategic advantage in streamlining the drug re-evaluation process and reducing the overall time in bringing new therapies to market. The substantial growth trajectory of the China Drug Repurposing Market is driven by enhanced Research and Development efforts, government support, and the need to optimize healthcare solutions, thus reinforcing the importance of all three Types within the landscape of China's evolving pharmaceutical industry. 

Moreover, the current trends signify that as the population ages and the prevalence of diseases increases, these Types will play a critical role in ensuring effective treatment options, thus creating vast opportunities and addressing substantial healthcare challenges within the region.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Drug Repurposing Market Therapeutic Area Insights**

The China Drug Repurposing Market within the Therapeutic Area segment showcases various compelling dynamics that shape its trajectory. This market has been witnessing enhancements driven by the increasing emphasis on cost-effective therapies and accelerated drug development processes. The Therapeutic Area encapsulates two essential categories: Same Therapeutic Area and Different Therapeutic Area, both of which are crucial for utilizing existing drugs in new contexts. The Same Therapeutic Area approach focuses on leveraging known drugs for additional indications, significantly reducing the time and resources needed for development. 

Meanwhile, the Different Therapeutic Area strategy promotes the exploration of existing drugs for entirely new conditions, which can lead to groundbreaking treatments and an expanded portfolio of therapeutic options. In China, the growing prevalence of chronic diseases and an aging population are contributing factors that amplify the importance of these strategies. The government’s initiatives to support Research and Development in drug repurposing reflect a robust commitment to enhancing healthcare delivery. 

The China Drug Repurposing Market revenue is poised to benefit from these therapeutic approaches as they not only present a lower-risk profile but also help streamline the approval processes, ultimately catering to the rising demand for effective and affordable healthcare solutions across the country. As these segments evolve, they offer numerous opportunities for innovation and heightened market growth.

**Drug Repurposing Market Drug Molecules Insights**

The Drug Molecules segment within the China Drug Repurposing Market presents a dynamic landscape, with key focus areas such as Biologics and Small Molecules. Biologics, derived from living organisms and recognized for their complex structures, have gained substantial traction due to their ability to target specific pathways in diseases. This niche is particularly important as it addresses unmet medical needs, especially in the realms of oncology and chronic disorders. Meanwhile, Small Molecules, known for their simpler, well-defined structures, remain significant due to their ease of synthesis and formulation, making them a staple in pharmaceutical development.

The integration of these drug types facilitates innovative approaches to drug repurposing, offering opportunities to optimize existing therapies while reducing development costs and time. This market segment is characterized by robust policies and support from the Chinese government aimed at enhancing Research and Development efforts, driving the growth of drug repurposing initiatives. Furthermore, the rapid evolution of biopharmaceuticals alongside advancements in genomic research underscores the importance of these drug molecules in addressing complex health challenges, underscoring their vital role in the broader China Drug Repurposing Market landscape.

**China Drug Repurposing Market Key Players and Competitive Insights**

The China Drug Repurposing Market is experiencing a dynamic evolution as pharmaceutical companies and research institutions explore novel applications for existing medications. This market is characterized by increased investment in research and development, fostering collaborations across various sectors aimed at accelerating the repurposing of drugs. Within this competitive landscape, companies are leveraging their existing portfolio of products to address unmet medical needs, particularly in response to the growing demand for efficient and cost-effective treatment options. The regulatory environment in China is also facilitating advancements in drug repurposing, resulting in increased market opportunities. 

As pharmaceutical players aim to gain a competitive edge, understanding the intricacies of this market is crucial for strategic positioning and long-term success.AstraZeneca holds a significant position in the China Drug Repurposing Market, primarily owing to its robust pipeline of innovative treatments and a strong commitment to research activities. The company's existing therapies in oncology and cardiovascular treatments offer potential avenues for repurposing in broader therapeutic areas, responding to the evolving health challenges faced by the Chinese population. 

AstraZeneca's established market presence is reinforced by its strong partnerships with local research institutions and healthcare providers, thereby enhancing its capability to expedite drug development processes. The company’s reputation for high-quality clinical research further strengthens its competitive advantage in identifying and executing repurposing initiatives efficiently. Additionally, AstraZeneca's ability to leverage its technological expertise and resources equips it to navigate the complexities of the fast-paced drug repurposing ecosystem in China.Merck & Co. is actively engaged in the China Drug Repurposing Market, focusing on the exploration of its extensive product portfolio for innovative applications beyond its original indications. 

The company’s strong pipeline includes key oncology drugs, vaccines, and other therapeutic agents that have shown promise in various clinical settings, enabling Merck & Co. to efficiently respond to the healthcare sector's needs within China. With notable strengths in research and development, the firm has established collaborations with local partners that facilitate knowledge exchange and expedite clinical trials. Merck & Co. has also engaged in strategic mergers and acquisitions that have further fortified its market position, allowing access to new technologies and expertise that enhance its drug repurposing capabilities. 

The company's commitment to improving patient outcomes and addressing unmet medical needs aligns perfectly with the growing demand for efficient repurposing strategies tailored to the Chinese market.

**Key Companies in the China Drug Repurposing Market Include**

**China Drug Repurposing Market Industry Developments**

In recent months, the China Drug Repurposing Market has seen significant developments, particularly with major companies like AstraZeneca, Merck and Company, Roche, and Pfizer actively engaging in new initiatives. The market has been bolstered by efforts aimed at enhancing drug accessibility and expediting approval processes due to the COVID-19 pandemic, leading to accelerated drug repurposing projects. In June 2023, Roche announced its interest in expanding its pipeline with a focus on targeted therapies that leverage repurposed drugs, showcasing an alignment with China's push for innovative healthcare solutions. 

Additionally, in July 2023, Johnson and Johnson announced a collaboration with a local biotech firm to explore the repurposing of existing drugs for rare diseases. The growth in this market segment is reflected in increasing investments, resulting in a projection of a 10% market valuation increase in 2023 compared to 2022. Companies like Bayer and Amgen are also evaluating their portfolios, reporting plans to enter into partnerships to advance drug repurposing strategies.

Over the past few years, initiatives in November 2021 by the Chinese government to promote drug repurposing have further stimulated this market, encouraging pharmaceutical stakeholders to innovate and adapt.

**China Drug Repurposing Market Segmentation Insights**

## Market Drivers

### Increasing Healthcare Expenditure

The rising healthcare expenditure in China is a pivotal driver for the drug repurposing market. As the government allocates more funds towards healthcare, the focus on innovative treatment options intensifies. In 2023, healthcare spending in China reached approximately $1.2 trillion, reflecting a growth rate of around 10% annually. This financial commitment facilitates research and development initiatives, particularly in drug repurposing, which offers a cost-effective alternative to developing new drugs from scratch. This trend allows for quicker access to therapies that can address unmet medical needs, enhancing patient outcomes and reducing overall healthcare costs.

### Regulatory Framework Enhancements

The evolving regulatory framework in China is a significant driver for the drug repurposing market. Recent reforms have streamlined the approval process for repurposed drugs, allowing for faster market entry. The National Medical Products Administration (NMPA) has introduced guidelines that prioritize the review of applications for repurposed drugs, recognizing their potential to address urgent health needs. This regulatory support is crucial, as it reduces the time and costs associated with bringing new therapies to market. As a result, the drug repurposing market is likely to experience accelerated growth, with more companies willing to invest in repurposing initiatives due to the favorable regulatory environment.

### Collaborative Research Initiatives

Collaborative research initiatives among academic institutions, pharmaceutical companies, and government bodies are fostering innovation within the drug repurposing market. In China, partnerships are increasingly common, as stakeholders recognize the potential of repurposed drugs to expedite the drug development process. For instance, the Chinese Academy of Sciences has launched several projects aimed at identifying new uses for existing medications. These collaborations not only enhance research capabilities but also attract funding, with investments in drug repurposing projects exceeding $500 million in recent years. Such initiatives are crucial for advancing the drug repurposing market, as they facilitate knowledge sharing and resource pooling, ultimately leading to more effective therapies.

### Aging Population and Chronic Diseases

China's demographic shift towards an aging population significantly impacts the drug repurposing market. With over 250 million individuals aged 60 and above, the prevalence of chronic diseases such as diabetes, hypertension, and cardiovascular conditions is on the rise. This demographic trend necessitates the development of effective treatment options, and drug repurposing emerges as a viable solution. By leveraging existing drugs for new therapeutic uses, the market can address the urgent healthcare needs of the elderly population. Furthermore, the Chinese government has recognized this challenge, implementing policies aimed at improving healthcare access and affordability, which further stimulates the drug repurposing market.

### Growing Focus on Personalized Medicine

The increasing emphasis on personalized medicine in China is shaping the drug repurposing market. As healthcare providers seek to tailor treatments to individual patient profiles, the potential for repurposed drugs to meet specific therapeutic needs becomes apparent. This trend is supported by advancements in genomics and biotechnology, which enable more precise targeting of therapies. The drug repurposing market stands to benefit from this shift, as existing drugs can be adapted for new indications based on genetic and biomarker information. Furthermore, the Chinese government is promoting personalized medicine through funding and policy initiatives, which could further enhance the market's growth prospects.

## Future Outlook

The [Drug Repurposing Market](https://www.marketresearchfuture.com/reports/drug-repurposing-market-22086) in China is poised for growth at 15.0% CAGR from 2025 to 2035, driven by technological advancements and increasing healthcare demands.

**New opportunities:**

- Development of AI-driven drug screening platforms
- Partnerships with biotech firms for clinical trials
- Expansion of telehealth services for patient monitoring

By 2035, the market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Type: Disease-centric (Largest) vs. Target-centric (Fastest-Growing)

The China drug repurposing market exhibits a diverse distribution among three primary segments: disease-centric, target-centric, and drug-centric approaches. Disease-centric strategies hold a significant market share, leveraging existing therapies to address various health conditions effectively. In contrast, target-centric approaches are witnessing rapid adoption, reflecting a shift towards more personalized medicine solutions that focus on specific biological targets. Drug-centric methodologies contribute to the segment but do not command the same market presence as the other two.

Disease-centric (Dominant) vs. Target-centric (Emerging)

The disease-centric approach is currently the dominant strategy in the market, driven by its ability to repurpose existing medications for new therapeutic uses. This method capitalizes on established safety profiles and streamlined regulatory pathways, making it an attractive option for pharmaceutical companies. Conversely, the target-centric method is an emerging trend that aligns with modern research focusing on specific molecular targets. This strategy often involves complex biomarker analyses and innovative treatment regimens, making it particularly appealing in areas like oncology and rare diseases. As research advances, both segments are likely to evolve, with target-centric approaches gaining traction as technologies improve.

### By Therapeutic Area: Same Therapeutic Area (Largest) vs. Different Therapeutic Area (Fastest-Growing)

The distribution of market share in the China drug repurposing market shows a clear dominance of the same therapeutic area segment, which maintains a significant lead. This segment appeals strongly to existing prescribers familiar with the therapeutic benefits and mechanisms of previously marketed drugs. Conversely, the different therapeutic area segment, while smaller, has been gaining traction as it provides innovative treatment possibilities and extends the utility of existing drugs into new therapeutic domains.

Growth trends reveal that the different therapeutic area segment is emerging as the fastest-growing, driven by increasing research and development efforts to explore new applications for existing therapies. This is often fueled by a mix of government support and investment in clinical trials to validate new indications. Meanwhile, the same therapeutic area continues to grow steadily, backed by a robust pipeline of established drugs being repositioned for enhanced efficacy or safety in treating similar conditions.

Same Therapeutic Area (Dominant) vs. Different Therapeutic Area (Emerging)

The same therapeutic area segment is characterized by its strong foothold in the market, where familiarity and established use drive significant demand. This segment benefits from existing clinical data supporting the efficacy of drugs within the same category, making it a preferred choice for healthcare professionals. On the other hand, the different therapeutic area segment represents an emerging opportunity within the market, capitalizing on innovative approaches to drug utilization. This segment is increasingly attractive as drug repurposing opens avenues for treating conditions that previously lacked effective therapies, positioning it for rapid growth as more successful case studies emerge and clinical validation progresses.

### By Drug Molecules: Biologics (Largest) vs. Small Molecule (Fastest-Growing)

In the China drug repurposing market, Biologics commands a significant share, largely due to its established presence and ongoing innovation in therapies. The growing recognition of their efficacy in addressing complex diseases contributes to this dominance. Conversely, the Small Molecule segment, while currently smaller in terms of market share, is witnessing rapid advancements and an increasing number of applications, making it a crucial focus for future developments.

The growth trends in this sector are driven by various factors including advancements in biotechnology, increased investment in R&D, and a rising demand for alternative therapies. Biologics continue to benefit from a robust pipeline and regulatory support, while the Small Molecule segment is evolving rapidly, propelled by new discoveries and enhanced drug formulations. This creates a dynamic landscape where both segments can thrive, albeit at different paces.

Biologics (Dominant) vs. Small Molecule (Emerging)

Biologics are characterized by their complex structures and are derived from living organisms, which makes them suitable for treating various chronic conditions and cancers. The increasing prevalence of these diseases, coupled with ongoing research in biologics, positions this segment as the dominant force in the market. On the other hand, Small Molecule drugs are generally low-cost, easier to manufacture, and have a wide range of applications. Their quick development cycle and emerging technologies for drug optimization provide a strong impetus for growth, allowing them to emerge as key players in the future of the China drug repurposing market.

## Competitive Benchmarking

The drug repurposing market in China is characterized by a dynamic competitive landscape, driven by the increasing need for cost-effective therapeutic solutions and the rapid advancement of biopharmaceutical technologies. Major players such as Pfizer Inc (US), Novartis AG (CH), and Bristol-Myers Squibb Company (US) are actively engaged in innovative strategies that emphasize research and development, strategic partnerships, and regional expansion. These companies are leveraging their extensive portfolios to explore new indications for existing drugs, thereby enhancing their market positioning and contributing to a more competitive environment.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with a mix of established pharmaceutical giants and emerging biotech firms. This fragmentation allows for a diverse range of therapeutic options, while the collective influence of key players fosters a competitive atmosphere that encourages innovation and collaboration.

In October  Pfizer Inc (US) announced a collaboration with a leading Chinese biotech firm to explore the repurposing of an existing cardiovascular drug for the treatment of neurodegenerative diseases. This strategic move not only highlights Pfizer's commitment to expanding its therapeutic reach but also underscores the potential for cross-industry partnerships to accelerate drug development timelines. Such collaborations may significantly enhance the efficacy of drug repurposing initiatives in the region.

In September  Novartis AG (CH) launched a new initiative aimed at repurposing its oncology portfolio to address rare diseases prevalent in China. This initiative reflects Novartis's strategic focus on addressing unmet medical needs while simultaneously diversifying its product offerings. By targeting niche markets, Novartis is likely to strengthen its competitive edge and foster long-term growth in the drug repurposing sector.

In August  Bristol-Myers Squibb Company (US) entered into a partnership with a local research institution to investigate the potential of repurposing an immunotherapy drug for autoimmune disorders. This collaboration not only enhances Bristol-Myers Squibb's research capabilities but also demonstrates the importance of local expertise in navigating the complexities of the Chinese healthcare landscape. Such strategic alliances are likely to play a crucial role in the success of drug repurposing efforts in the region.

As of November  current trends in the drug repurposing market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in research processes. Strategic alliances are shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift may ultimately lead to more effective and accessible therapeutic options for patients in China.

## Recent News & Developments

In recent months, the China Drug Repurposing Market has seen significant developments, particularly with major companies like AstraZeneca, Merck and Company, Roche, and Pfizer actively engaging in new initiatives. The market has been bolstered by efforts aimed at enhancing drug accessibility and expediting approval processes due to the COVID-19 pandemic, leading to accelerated drug repurposing projects. In June 2023, Roche announced its interest in expanding its pipeline with a focus on targeted therapies that leverage repurposed drugs, showcasing an alignment with China's push for innovative healthcare solutions. 

Additionally, in July 2023, Johnson and Johnson announced a collaboration with a local biotech firm to explore the repurposing of existing drugs for rare diseases. The growth in this market segment is reflected in increasing investments, resulting in a projection of a 10% market valuation increase in 2023 compared to 2022. Companies like Bayer and Amgen are also evaluating their portfolios, reporting plans to enter into partnerships to advance drug repurposing strategies.

Over the past few years, initiatives in November 2021 by the Chinese government to promote drug repurposing have further stimulated this market, encouraging pharmaceutical stakeholders to innovate and adapt.

## Report Scope

| MARKET SIZE 2024 | 30.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 34.5(USD Million) |
| MARKET SIZE 2035 | 139.6(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 15.0% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Pfizer Inc (US), Novartis AG (CH), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), AstraZeneca PLC (GB), Eli Lilly and Company (US), Gilead Sciences Inc (US), Amgen Inc (US) |
| Segments Covered | Type, Therapeutic Area, Drug Molecules |
| Key Market Opportunities | Emerging technologies enhance drug repurposing efficiency, addressing unmet medical needs and regulatory pathways. |
| Key Market Dynamics | Growing emphasis on regulatory compliance and technological advancements drives innovation in the drug repurposing market. |
| Countries Covered | China |

## Frequently Asked Questions

**Q: What was the market valuation of the China drug repurposing market in 2024?**
A: The market valuation was $30.0 Million in 2024.

**Q: What is the projected market valuation for the China drug repurposing market by 2035?**
A: The projected valuation for 2035 is $139.6 Million.

**Q: What is the expected CAGR for the China drug repurposing market during the forecast period 2025 - 2035?**
A: The expected CAGR is 15.0% during the forecast period 2025 - 2035.

**Q: Which companies are considered key players in the China drug repurposing market?**
A: Key players include Pfizer Inc, Novartis AG, Bristol-Myers Squibb Company, Johnson & Johnson, AstraZeneca PLC, Eli Lilly and Company, Gilead Sciences Inc, and Amgen Inc.

**Q: What are the main segments of the China drug repurposing market?**
A: The main segments include Type, Therapeutic Area, and Drug Molecules.

**Q: What was the valuation for the Disease-centric segment in 2024?**
A: The valuation for the Disease-centric segment was $10.0 Million in 2024.

**Q: How does the Drug-centric segment perform in terms of valuation?**
A: The Drug-centric segment had a valuation of $8.0 Million in 2024 and is projected to reach $33.6 Million by 2035.

**Q: What is the valuation for the Small Molecule segment in 2024?**
A: The Small Molecule segment was valued at $20.0 Million in 2024.

**Q: What is the projected valuation for the Different Therapeutic Area segment by 2035?**
A: The projected valuation for the Different Therapeutic Area segment is $72.6 Million by 2035.

**Q: What was the valuation for Biologics in 2024?**
A: The valuation for Biologics was $10.0 Million in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/china-drug-repurposing-market-52395*